Manidipine (dihydrochloride)

Manidipine dihydrochloride is a third-generation, lipophilic, orally active and highly vasoselective calcium channel antagonist (IC₅₀ = 2.6 nM in guinea-pig ventricular cells) and acts as an antihypertensive agent. Manidipine effectively reduces blood pressure as well as improving insulin sensitivity, renal protection, and antiatherosclerotic activity. Manidipine also exerts anti-inflammatory activity mediated by NF-κB and antiviral activity against many flavivirus and negative-strand RNA viruses through the inhibition of calcium channel. Manidipine is widely applied to research of cardiovascular, metabolic disease and infection^{[1][2][3][4][5][6]}. IC50 & Target:IC50: 2.6 nM (calcium channel)^[6] In Vitro:Manidipine dihydrochloride (1 μM, 42 h) suppresses IL-6 secretion in lipoproteins-induced HUVEC^[3].
Manidipine dihydrochloride (1 μM, 16 h) suppresses IL-6 secretion in 10 ng/mL IL-1, 10 ng/mL IFN-γ, and 25 ng/mL TNFα treated THP-I ^[3].
Manidipine dihydrochloride (20 mg/mL, 48/20 h) inhibits propagation/genome replication of SFTSV (a negative-strand RNA virus) in SW13 cells^[4].
Manidipine dihydrochloride (20 mg/mL, 48 h) interferes SFTSV N-induced inclusion body formation in Huh-7 cells^[4].
In Vivo:Manidipine dihydrochloride (10 mg/kg, i.p., b.i.d. at day 4, day 5) prolongs survival in SFTSV-infected mice^[4].
Manidipine dihydrochloride (25 mg/kg, i.p., b.i.d. for 2 d, then daily for 19 d) protects mice from JEV infection^[5].
Manidipine dihydrochloride (3 mg/kg, i.g., once per day, 7 d) prevents isoproterenol-induced left ventricular hypertrophy in rats^[7].